HDAC9 and diffuse large B-cell lymphoma: Various ongoing clinical trials are also exploring the combined treatment of HDAC inhibitors with PD-1 monoclonal antibodies in the treatment of HL, DLBCL, FL, PTCL, CTCL, AITL, ENKT, and HLH secondary to ENKT (Table 4).